Psychedelics and Anxiety: What the Research Shows
Excessive worry and fear that interferes with daily life. Research summaries and safety screening; Gabriel doesn't give psychedelic dosing.
Overview
Anxiety disorders involve persistent worry and fear that are hard to control. Psychedelic research for anxiety has focused on generalized anxiety disorder and on anxiety in people facing a serious illness.
The experience itself can bring on anxiety, so trials pair it with preparation, a trained facilitator during the session and follow-up support.
Substances Being Studied
Cannabis
StrongCannabis contains more than 100 cannabinoids; THC (tetrahydrocannabinol) and CBD (cannabidiol) are the most studied. Unlike classic psychedelics, cannabis works through the endocannabinoid system rather than serotonin receptors. THC causes euphoria, relaxation, altered perception and increased appetite, while CBD is not intoxicating. FDA has approved several cannabinoid medicines: Epidiolex, a CBD medicine, for certain seizure disorders, and dronabinol and nabilone for chemotherapy-related nausea and appetite loss. Researchers have studied cannabis for chronic pain, nausea, MS spasticity, sleep, PTSD, anxiety and appetite loss in cancer and HIV/AIDS; the evidence is strongest for chronic pain in adults, chemotherapy-related nausea and MS spasticity, and varies for the rest. Cannabis has been used medicinally in many cultures for thousands of years. Risks include dependence, cognitive effects with heavy use, anxiety or paranoia in some people, psychosis in vulnerable people, and lung irritation from smoking. Cannabis interacts with many medications, including blood thinners and seizure medicines, so tell your clinician and pharmacist if you use it.
Ketamine
StrongKetamine is a dissociative anesthetic that blocks NMDA receptors in the brain, which affects glutamate signaling and may help rebuild connections between nerve cells weakened by chronic stress and depression. Unlike classic psychedelics, it does not work mainly through serotonin receptors, and it can act within hours rather than weeks. Esketamine (Spravato), a nasal spray made from one form of ketamine, was FDA-approved in 2019 for treatment-resistant depression alongside an oral antidepressant, and in January 2025 as a treatment on its own; in the monotherapy trial, 22.5% of people on esketamine reached remission at four weeks versus 7.6% on placebo. Esketamine is given only in certified clinics, with monitoring after each dose. Racemic ketamine is not FDA-approved for any psychiatric condition; clinics that give IV ketamine for depression use it off-label. In October 2023, FDA warned about compounded ketamine for psychiatric use, including oral forms prescribed by telehealth for use at home, because no one monitors patients during treatment. During a supervised treatment, ketamine causes dissociation, altered time perception and dreamlike states that usually fade within an hour or two.
MDMA
StrongMDMA is a synthetic empathogen that increases the release of serotonin, dopamine and norepinephrine. Unlike classic psychedelics, it mainly increases feelings of closeness and lowers fear, usually without hallucinations, which is why researchers have studied it alongside talk therapy for PTSD. In two Phase 3 trials run by MAPS and Lykos Therapeutics, about two thirds of participants who received MDMA with therapy no longer met the criteria for PTSD at the end of the study. In August 2024, FDA declined to approve it, citing concerns about study design, functional unblinding (most participants could tell whether they had received MDMA) and missing data, and asked for another Phase 3 trial. In August 2026 the company, now called Resilient Pharmaceuticals, was reported to have resubmitted its application; as of October 2026, FDA has not announced a decision. Since July 2023, specially authorized psychiatrists in Australia can prescribe MDMA for PTSD, and a 2024 Utah law (SB 266) allows a limited hospital-based pilot program. Researchers think MDMA may work by quieting the brain's fear response while therapy helps people revisit and reprocess traumatic memories.
Psilocybin
StrongPsilocybin is a naturally occurring psychedelic compound found in more than 200 species of mushrooms. In the body it converts to psilocin, which activates serotonin 5-HT2A receptors in the brain, changing perception, mood and thinking for several hours. In clinical trials, psilocybin given with psychological support has reduced depression symptoms within days, with effects lasting weeks to months for some participants. Compass Pathways has run two Phase 3 trials of COMP360, a synthetic psilocybin, for treatment-resistant depression: in COMP005 (results June 2025) it beat placebo by 3.6 points on the MADRS depression scale at week 6, and in COMP006 (results February 2026) it beat a very low comparison dose by 3.8 points. As of October 2026, psilocybin is not FDA-approved; Compass says it is completing its application to FDA. Researchers at Johns Hopkins, NYU Langone, Imperial College London and other centers have also studied psilocybin for anxiety and depression in people with cancer, alcohol and tobacco use disorders, and obsessive-compulsive disorder. Trials pair it with preparation and follow-up sessions with trained therapists, and screen people carefully before treatment.
Ayahuasca
ModerateAyahuasca is a traditional Amazonian brew, usually made from the Banisteriopsis caapi vine and Psychotria viridis leaves. The vine contains harmala alkaloids that act as MAO inhibitors (MAOIs), which let the DMT in the leaves become active when swallowed, producing a visionary experience that usually lasts 4 to 6 hours. Indigenous peoples of the Amazon have used ayahuasca for generations in ceremonies for healing, spiritual guidance and community ritual. A small randomized trial in Brazil (2019) found that a single dose reduced depression scores in people with treatment-resistant depression compared with placebo, and observational studies have looked at ayahuasca for substance use disorders. Because the brew contains MAOIs, it can interact dangerously with antidepressants and many other medicines and substances. The experience usually involves vomiting and diarrhea, which traditional practitioners consider part of the ceremony.
LSD
ModerateLSD (lysergic acid diethylamide) is a potent semi-synthetic psychedelic first made by Albert Hofmann at Sandoz Laboratories in 1938. It activates serotonin 5-HT2A receptors and changes perception, mood and thinking for 8 to 12 hours. In the 1950s and 60s it was studied for alcoholism and anxiety before research stopped under prohibition. Modern trials have returned: Definium Therapeutics (formerly MindMed) reported positive Phase 3 results for its LSD drug candidate, DT120, in major depression (Emerge, June 2026) and generalized anxiety disorder (Voyage, August 2026), where it reduced symptoms more than placebo. As of October 2026, LSD is not FDA-approved; the company has said it plans to apply in 2027. A 2025 phase 2a trial of repeated low doses of LSD for adult ADHD did not beat placebo on its primary outcome. Earlier work at the University of Basel studied LSD-assisted therapy for anxiety in people with life-threatening illness, and neuroimaging studies at Imperial College London showed how LSD changes communication between brain networks.
DMT / 5-MeO-DMT
EmergingDMT (N,N-dimethyltryptamine) and its close relative 5-MeO-DMT are among the most potent psychedelics known, with intense but short effects. N,N-DMT is found in many plants and is the active compound in ayahuasca; inhaled, its effects last about 15 to 30 minutes and often include vivid visual patterns and a strong sense of meeting other beings. 5-MeO-DMT, found in some plants and in the venom of the Sonoran Desert toad (Incilius alvarius), tends to produce a loss of the sense of self rather than visual imagery. In a small phase 2a trial led at Imperial College London and published in Nature Medicine in February 2026, a single IV dose of DMT (SPL026) given with psychological support reduced depression scores more than placebo at two weeks. In a 2025 Phase 2b trial in 193 people with treatment-resistant depression, Beckley Psytech's intranasal 5-MeO-DMT (BPL-003) reduced depression scores more than a very low comparison dose, with no serious adverse events; a Phase 3 program was planned for 2026. Neither is FDA-approved. The trials use synthetic compounds. Toad-derived 5-MeO-DMT has no verified history of traditional indigenous use (modern toad ceremonies date from about 2015), and collecting the venom harms wild toad populations.
Peyote / Mescaline
TraditionalPeyote (Lophophora williamsii) is a small, spineless cactus containing mescaline as its primary psychoactive alkaloid. Sacred to the Native American Church (NAC), which has over 400,000 members across 50+ tribes, peyote serves as a holy sacrament in all-night ceremonies for spiritual communion, healing, and addressing personal and social imbalances. The NAC originated around 1885 among Kiowa and Comanche tribes, blending indigenous spirituality with Christian elements to preserve peyote traditions during persecution. Ceremonies occur in tipis around a crescent-shaped altar and sacred fire, running from Saturday evening through Sunday morning. Participants consume peyote (never smoked, only eaten dry, ground, or as tea) with prayer, singing, and contemplation, seeking guidance, healing, and communion with God and spirits. The Peyote Spirit is considered a deity providing visions, promoting brotherly love, family care, steady work, and abstinence from alcohol. Peyote contains more than 50 alkaloids; anthropologists have described sobriety as a goal of many Native American Church members, but controlled clinical research is minimal. Peyote is also a slow-growing, threatened cactus, and Native American Church leaders have asked non-Native people not to seek it out. The experience typically lasts 10-12 hours with enhanced perception, emotional openness, and spiritual insight.
San Pedro / Huachuma
TraditionalSan Pedro (Echinopsis pachanoi), known as Huachuma in indigenous traditions, is a mescaline-containing cactus native to the Andes mountains of Peru, Bolivia, Ecuador, and surrounding regions. With over 4,000 years of ceremonial use, it is one of the oldest entheogens in the Americas, predating psilocybin mushroom use. Archaeological evidence from Peru's Chavín culture (1500 BCE) shows stone carvings of shamans holding the cactus. The Inca used San Pedro in ceremonies at Cusco, Machu Picchu, and the Sacred Valley for spiritual communion with deities, purification, divination, healing, and governance counsel. The primary psychoactive compound, mescaline, increases prefrontal cortex activity for emotional regulation and planning while producing heart-opening, empathogenic effects alongside visual enhancements. Traditional curanderos (healers) in Peru and Ecuador use San Pedro tea in blended indigenous-modern medicine for shamanic healing, enhancing perception, awakening intuition, and diagnosing mind-body-spirit imbalances. The experience, lasting 10-14 hours, typically brings euphoria, compassion, empathy, enhanced environmental awareness, and insights into personal problems. Modern clinical research on mescaline is very limited, so these traditional uses have not been tested in controlled trials.
What the Research Shows
In August 2026, an LSD drug candidate (DT120) reduced anxiety scores more than placebo in a Phase 3 trial for generalized anxiety disorder; it is not FDA-approved. Two 2016 randomized trials at Johns Hopkins and NYU found that psilocybin with psychological support reduced anxiety and depression in people with cancer. As of October 2026, no psychedelic is FDA-approved for anxiety.
Safety Considerations
- •The experience can temporarily increase anxiety.
- •Benzodiazepines and other anxiety medicines can interact. Never stop or change a prescribed medicine without your prescriber.
- •Trained support during and after a session is part of every studied treatment.
Safety screening
Psychedelics are not safe for everyone. Talk with a licensed clinician first, especially if any of these apply to you:
- Antidepressants such as SSRIs and SNRIs, and other medicines that raise serotonin (tramadol, for example): they can blunt the effect of psychedelics, and with some substances, such as MDMA and ayahuasca, raise the risk of serotonin syndrome.
- Lithium: seizures have been reported when lithium is combined with classic psychedelics such as psilocybin and LSD.
- MAOIs, including the MAOIs in ayahuasca: dangerous interactions with many medicines, other substances and some foods.
- Heart disease, high blood pressure, or a heart rhythm problem such as long QT syndrome.
- A personal or family history of psychosis, schizophrenia or bipolar disorder.
- Pregnancy or breastfeeding.
Never stop or change a prescribed medicine without your prescriber.
Gabriel doesn't give psychedelic dosing and doesn't help anyone obtain psychedelics. This page explains research and risks; it is not medical advice.
If you're in crisis, call or text 988 (Suicide and Crisis Lifeline). For a medical emergency, call 911.
Related Conditions
Questions? Ask Gabriel
Gabriel can help you find and book licensed clinicians who offer ketamine or esketamine treatment. Gabriel doesn't prescribe ketamine.
Ask Gabriel